New York, Feb 26, 2026, 06:07 (EST) — Premarket
- Healthcare Triangle shares jumped roughly 66% ahead of the bell, most recently trading at $9.67.
- QuantumNexis’s Ziloy mental health platform is set to be folded into Malaysia’s TNG eWallet, the company said.
- Traders are eyeing whether the spike will stick at the open, following a recent reverse split that reshaped the stock.
Healthcare Triangle Inc (HCTI) surged nearly 66% to $9.67 in U.S. premarket action Thursday, coming off a close of $5.81 the previous day. Roughly 1.6 million shares had changed hands before the bell.
After the announcement, the company revealed its QuantumNexis arm had entered a partnership with TNG Digital, aiming to roll out digital mental-health tools for TNG eWallet’s 25 million-plus Malaysian users. According to the statement, the service operates on a transaction-based model. Malaysia is projected to bring in what the company calls a “growing six-figure” boost across the next two quarters. Newswire
That’s relevant now, with Healthcare Triangle’s stock swinging wildly and the company pushing to prove its newer platform can actually bring in paying users instead of just generating pilot buzz.
Traders are watching to see how fast the rollout translates into actual numbers, and if the company adjusts its outlook past the upcoming quarters. Thin liquidity in early trading, as always, can swing things sharply in either direction.
QuantumNexis chairman Suresh Venkatachari described the agreement as a move to “enable accessible, clinically validated support for millions,” the release stated. The company plans to integrate its Ziloy platform directly into TNG eWallet. PR Newswire
Healthcare Triangle finished the last regular session at $5.81, after swinging from $5.52 up to $6.39. Roughly 311,000 shares were traded.
Healthcare Triangle pulled off a 1-for-60 reverse stock split earlier this month, aiming to raise its per-share price—though the company’s business value stays put. The move is part of its effort to stick to Nasdaq’s listing requirements.
The company’s flagged dollar boost for the near term? Still on the lighter side. Execution’s anything but a sure bet—adoption might drag, marketing could eat up more budget than projected, and partnerships risk stalling out on integration or regulatory snags.
